p
r
i
m
e
med
i
c
i
n
e
About
_
Leadership
_
Board of Directors
_
Scientific Founders
_
Scientific Advisory Board
_
Our Partners
_
Science
_
How Prime Editing Works
_
Versatile
_
Precise
_
Dual Flap
_
Efficient
_
Passige
_
Broad
_
Scientific Publications & Presentations
_
Pipeline
_
Our Pipeline
_
Clinical Programs
_
Patients & Caregivers
_
Our Commitment
_
About Our Programs
_
External Resources
_
Patient Stories
_
Contact Us
_
Investors
_
Careers
_
Development of PM359, a Prime Edited CD34+ cell drug product for the treatment of p47phox Chronic Granulomatous Disease